Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

ABSTRACT:

Objective

To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington's disease (HD).

Methods

In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals with HD and clinical signs of apathy according to the Structured Clinical Interview for Apathy-Dementia (SCIA-D), but not depression (n = 40) were randomized to receive either bupropion 150/300mg or placebo daily for 10 weeks. The primary outcome parameter was a significant change of the Apathy Evaluation Scale (AES) score after ten weeks of treatment as judged by an informant (AES-I) living in close proximity with the study participant. The secondary outcome parameters included changes of 1. AES scores determined by the patient (AES-S) or the clinical investigat

SUBMITTER: Gelderblom H 

PROVIDER: S-EPMC5360242 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature